Biogen Idec is presenting new clinical data on its neurology portfolio at the 2012 American Academy of Neurology (AAN) annual meeting this week.

During the conference in New Orleans, the company will provide 49 company-sponsored platform and poster presentations showcasing its various promising therapies for unmet needs in the neurodegenerative disease field.

New data will highlight the safety and efficacy of the marketed products Tysabri, Avonex and Fampyra, as well as results from investigational trials of key late-stage compounds such as BG-12, PEGylated interferon beta-1a and daclizumab high-yield process.

These therapies offer various benefits for multiple sclerosis, while another new drug on display - dexpramipexole - represents Biogen Idec's effort to branch out into amyotrophic lateral sclerosis.

Dr Douglas Williams, executive vice-president for research and development at Biogen Idec, said: "We will continue to make progress toward addressing significant unmet medical needs in neurology."

In February, the company announced that it has filed for US regulatory approval of BG-12, based on positive data from the Define and Confirm phase III trials.